CCF Webinar: Immunotherapy (Rilvegostomig) plus chemo for patients with BTC after resection

Patients who undergo curative surgery for BTC (Biliary Tract Cancers) may relapse and adjuvant chemotherapy is given after surgery to lower this risk. This study will evaluate if the addition of immunotherapy to chemotherapy can reduce the risk of relapse more than chemotherapy alone. This webinar is to raise awareness of a Phase III study to evaluate an investigational immunotherapy agent, rilvegostomig, in combination with chemotherapy for the adjuvant treatment of BTC. ARTEMIDE-Biliary-01 is a randomized, double-blind, placebo-controlled, study which will assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1(tegafur/ gimeracil/ oteracil) or gemcitabine/cisplatin) as adjuvant treatment.
Recorded on June 13, 2024

[@ntang]

I think the recording is broken, there seems to be no speaker audio on this video.